Volume 5.49 | Dec 12

Cord Blood News 5.49 December 12, 2013
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Long-Term Cultured Mesenchymal Stem Cells Frequently Develop Genomic Mutations but Do Not Undergo Malignant Transformation
To determine whether in vitro expansion influences the genomic stability of human umbilical cord mesenchymal stem cells (hUC-MSCs), scientists maintained nine hUC-MSC clones in long-term culture and comparatively analyzed them at early and late passages. [Cell Death Dis] Full Article
New Cord Banking Software Solution from STEMSOFT
PUBLICATIONS (Ranked by impact factor of the journal)
Platelet-Secreted MicroRNA-223 Promotes Endothelial Cell Apoptosis Induced by Advanced Glycation End Products via Targeting the Insulin-like Growth Factor 1 Receptor
Incubation of platelets microvesicles (P-MVs) with HUVECs, which had significantly lower levels of microRNA-223 (miR-223) than platelets, showed that P-MVs effectively delivered miR-223 into HUVECs. [J Immunol] Abstract

Ex Vivo Expansion of Hematopoietic Stem- and Progenitor Cells from Cord Blood in Coculture with Mesenchymal Stroma Cells from Amnion, Chorion, Wharton’s Jelly, Amniotic Fluid, Cord Blood, and Bone Marrow
Scientists investigated whether bone marrow-derived (mesenchymal stroma cells) MSCs, which have to be obtained in an invasive procedure, introduce a further donor and increases the risk of transmissible infectious diseases for the patient can be replaced by MSCs from amnion, chorion, Wharton’s jelly, amniotic fluid, and cord blood (CB), which can be isolated from placental tissue which is readily available when CB is sampled. [Tissue Eng Part A] Abstract

A Novel Reduced Intensity Conditioning Regimen for Unrelated Umbilical Cord Blood Transplantation in Children with Non-Malignant Diseases
Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections were enrolled in a novel reduced intensity conditioning protocol consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan and thiotepa followed by single umbilical cord blood transplantation. [Biol Blood Marrow Transplant] Abstract

Role of FGF10 on Tumorigenesis by MS-K
The role of fibroblast growth factor-10 (fgf-10) on tumor growth was studied. MS-K enhanced more proliferation of endothelial cells by direct co-culture than NFSA, and rFGF10 supported the proliferation of HUVEC in combination with vascular endothelial growth factor-A. [Genes Cells] Abstract

A Preliminary Study on the Construction of Double Suicide Gene Delivery Vectors by Mesenchymal Stem Cells and the In Vitro Inhibitory Effects on SKOV3 Cells
Researchers aimed to investigate the efficacy of using human umbilical cord blood-derived mesenchymal stem cells as gene delivery vectors in the treatment of ovarian cancer. [Oncol Rep] Abstract

Sox2 Suppression by miR-21 Governs Human Mesenchymal Stem Cell Properties
Investigators isolated two subpopulations of fetal mesenchymal stem cells from amniotic fluid known as spindle-shaped and round-shaped cells and characterized them on the basis of their phenotypes, pluripotency, proliferation rates, and differentiation potentials. [Stem Cell Transl Med] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation
This review summarizes advances in immune recovery after haploidentical hematopoietic stem cell transplantation, focusing on the immune subsets that are likely to have the greatest impact on clinical outcomes. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Hear from the leaders in the Cell Culture sector!
Multiplying Stem Cells from Umbilical Cord Blood Donations Increases Survival of Leukemia and Lymphoma Patients
Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers. Now a study led by a Loyola University Medical Center oncologist has found that growing cord blood stem cells in a laboratory before transplanting them into patients significantly improves survival. [Press release from Loyola University Health System discussing research presented at the 55th annual meeting of the American Society of Hematology, New Orleans] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
Child with Cerebral Palsy Treated with Umbilical Cord Blood Derived Autologous Stem Cells
Cryo-Save Group N.V. announced that a 4-year-old girl in Spain received an infusion of stem cells derived from her own umbilical cord blood for the treatment of her cerebral palsy. [PR Newswire Association LLC] Press Release

UTHealth Researchers Study Stem Cell Treatments for Children with CP
A first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy (CP) has begun at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The double-blinded, placebo-controlled study’s purpose includes comparing the safety and effectiveness of banked cord blood to bone marrow stem cells. [The University of Texas Health Science Center at Houston] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Canadian Blood and Marrow Transplant Group 2014
June 11-14, 2014
Halifax, Canada

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

PhD Studentship – iNKT Cells to Prevent Graft versus Host Disease (University of Birmingham)

Postdoctoral Associate – Graft-vs.-Host Disease and Graft-vs.-Leukemia in Mouse Models (Yale University School of Medicine)

Clinical Researcher – Hematopoietic Stem Cell Transplant Program (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Fellows – Isolation of Stem Cells from Placenta and Amniotic Fluid (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.
Learn more about Cord Blood News: Archives | Events | Contact Us